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Abstract
Background: According to some studies, almost 40% of depressive patients – half of them
previously undetected – are diagnosed of bipolar II disorder when systematically assessed for
hypomania. Thus, instruments for bipolar disorder screening are needed. The Mood Disorder
Questionnaire (MDQ) is a self-reported questionnaire validated in Spanish in stable patients with
a previously known diagnosis. The purpose of this study is to evaluate in the daily clinical practice
the usefulness of the Spanish version of the MDQ in depressive patients.
Methods: Patients (n = 87) meeting DSM-IV-TR criteria for a major depressive episode, not
previously known as bipolar were included. The affective module of the Structured Clinical
Interview (SCID) was used as gold standard.
Results: MDQ screened 24.1% of depressive patients as bipolar, vs. 12.6% according to SCID. For
a cut-off point score of 7 positive answers, sensitivity was 72.7% (95% CI = 63.3 – 82.1) and
specificity 82.9% (95% CI = 74.9–90.9). Likelihood ratio of positive and negative tests were 4,252
y 0,329 respectively.
Limitations: The small sample size reduced the power of the study to 62%.
Conclusion: Sensitivity and specificity of the MDQ were high for screening bipolar disorder in
patients with major depression, and similar to the figures obtained in stable patients. This study
confirms that MDQ is a useful instrument in the daily clinical assessment of depressive patients.
Introduction
Accurate recognition of bipolar disorders remains elusive,
mainly in those patients presenting to the clinician with a
major depressive episode. It has been found that almost
40% of patients suffering a major depressive episode,
when carefully assessed and systematically searched for
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lar II disorder, but only half of them were previously diag-
nosed by their clinicians[1].
On the other hand, use of antidepressants, mainly tricy-
clics or MAO inhibitors [2] and very likely dual antide-
pressants [3,4] has been related with manic switch, rapid
cycling or worse outcome in bipolar patients. Thus, a
more accurate diagnosis of those apparently "pseudouni-
polar" patients might lead to a more adequate treatment
and subsequently contribute to reduce the personal and
financial burdens related to an incorrect diagnosis [5].
A variety of instruments have been developed for the
screening of hypomanic symptoms [6,7]. The Mood Dis-
order Questionnaire (MDQ) has been the more exten-
sively used [8] The MDQ is a self-reported, 13-item "yes/
no" questionnaire. It is easy to understand, complete and
correct. The MDQ has been designed for the identification
of hypomanic or manic symptoms throughout the life
span. The questions are based on DSM-IV criteria and clin-
ical experience. Furthermore, the MDQ includes a ques-
tion about simultaneity of symptom occurrence and
another question regarding interference with the func-
tioning of the subject.
The MDQ has shown, in the validation carried out by his
authors in a sample of psychiatric patients [8], a sensitivity
of 0.73 (95% CI = 0.65–0.81) and a specificity of 0.90
(95% CI = 084–0.96) for a cut-off point score of 7 positive
answers or higher. That means that seven out of 10
patients with bipolar disorder, and 9 out of 10 subjects
without this disorder could be adequately classified. Sev-
eral studies have been conducted with the MDQ for vali-
dation of the different language versions and with
epidemiological purposes as well [9-14]. Furthermore, a
version of the MDQ for the adolescent population has
also been validated [15].
The validation of the Spanish version of the MDQ has
been done in stable patients with a previously known
diagnosis of major depression or bipolar disorder [16].
This version achieved, for a cut-off point score of 7 posi-
tive answers, similar sensitivity and specificity rates than
the original version.
The purpose of this study is to evaluate the daily clinical
usefulness of the Spanish version of the MDQ as a screen-
ing instrument for bipolarity in a sample of patients with
a diagnosis of major depression, and not previously
known as bipolar patients.
Methods
This study has been conducted in five general psychiatry
Mental Health Centers. Each investigator included new
consecutive patients meeting DSM IV-TR criteria for a
major depressive episode, (single o recurrent). Patients
were 18 years or older. Patients with a previously known
diagnosis of bipolar disorder or other psychotic disorder,
depression due to a medical condition, substance abuse or
dependence were excluded from the study.
Patients meeting inclusion criteria completed the Spanish
version of the MDQ after signing an informed consent.
Afterwards, patients were interviewed with the affective
module of the SCID (First et al., 1997). Other assessment
instruments used were the 17-item Hamilton Depression
Rating Scale ([17,18], Young Mania Rating Scale [19] and
the Global Assessment of Functioning (axis V of DSM-IV-
TR).
The study protocol was approved by the Ethics Committee
of the University Hospital La Paz in Madrid.
Analysis of data includes any possible association
between some clinical variables and unipolar/bipolar dis-
order diagnosis according to SCID. Chi-square test was
used for qualitative variables, while a difference in mean
t-test was employed for quantitative ones.
For the MDQ, sensitivity and specificity were analyzed
and plotted as a receiver-operating-characteristics curve.
SCID was used as the gold standard. A Mood Disorder
Questionnaire screening score of 7 or more items was
used, following the recommendation of its authors [8].
Besides, the likelihood ratios for a positive and a negative
test were calculated. This statistics would be preferred,
instead of predictive values, because they are independent
of the prevalence of the disease in the population. Larger
values of a positive likelihood ratio indicate a better
capacity to diagnose the illness. The smaller likelihood
ratio of a negative test indicates a higher chance of being
a true negative.
All the statistical analyses were performed using SPSS (ver-
sion 14.0).
Results
A total of 90 patients were included in the study. Three
patients were excluded of the analysis because of a major
protocol violation. According to the SCID, 87.4% (n = 76)
of the sample population was classified as unipolar,
whereas 12.6% (n = 11) were diagnosed of bipolar disor-
der.
Table 1 shows sociodemographic and clinical features of
the sample population. A longer time from onset of the
illness to the diagnosis in those patients suffering bipolar
depression (10,9 years) was the only statistically signifi-
cant difference observed (p = 0.004; 95% CI = 3.6–18.5).Page 2 of 5
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screened 24.1% of the total sample as bipolar. Mean
number of positive answers were 3.8 (SD 2.6) and 8.0 (SD
2.3) in the unipolar and bipolar subgroups of patients
respectively, (p < 0.0001). For the cut-off point score of 7,
sensitivity was 72.7% (95% CI = 63.3 – 82.1), and specif-
icity 82.9% (95% CI = 74.9–90.9). The analysis of the
Receiver Operating Characteristic (ROC) curve (Fig. 1)
gives an area under the curve value of 0.778 (95% CI =
0.617–0.94). Likelihood ratio of positive test and likeli-
hood ratio of negative test were 4.252 and 0.329 respec-
tively.
Discussion
In this study we have assessed the performance of the
Spanish version of the MDQ for screening bipolar disor-
der in a sample of patients with a major depressive epi-
sode and an unknown previous diagnosis of bipolar
disorder. Regarding sensitivity, our results are similar to
those reported in the studies conducted for the validation
of the original [8] and the Spanish [16] version of MDQ.
Nevertheless, a lower specificity was obtained in our study
compared with previous studies (82.9% vs. 90%).
Epidemiological data showing the prevalence of bipolar
disorder in patients with a major depressive episode are
controversial [1,20]. Thus, using likelihood ratios, a meas-
ure which does not depend on pre-test probability of dis-
ease, might more accurately express the usefulness of
MDQ. In our study, negative likelihood ratio was low,
suggesting that MDQ may be an effective instrument for
detecting those depressive patients who are not very likely
bipolar. This finding could have a relevant clinical appli-
cation because bipolar disorder could be ruled out with
fairly high degree of confidence in those patients with a
major depressive episode and a negative result in the
MDQ. Thus, use of antidepressants – at present of first
choice in unipolar but not in bipolar depression – could
be safer. On the other hand, a positive result in the MDQ
requires a more detailed clinical evaluation. We agree with
the author of the MDQ [21], that a clinical confirmation
of bipolar disorder is always mandatory, since MDQ may
wrongly identify a patient as bipolar when that is not the
case. In our study the MDQ screened 24.1% of a clinical
Table 1: Sociodemographic and Clinical Characteristics of the Sample Population
Diagnosis according to SCID
Characteristics Unipolar N = 76 Bipolar N = 11
Sex: male; N (%) 21 (27.6) 4 (36.4)
Age; Mean (SD) 45.0 (12.0) 40.0 (13.0)
Age of onset; Mean (SD) 28.2 (9.9) 23.5 (7.5)
Years of evolution from the first episode; Mean (SD) 7.4 (9.2)* 18.4 (12.9)*
History of previous episodes; N (%) 37 (48.7) 9 (81.8)
Family history of bipolar disorder; N (%) 7 (9.3) 2 (18.2)
HDRS score; Mean (SD) 23.5 (4.8) 22.2 (5.8)
YMRS score; Mean (SD) 2.3 (1.6) 2.9 (2.0)
GAF score; Mean (SD) 63.0 (13.2) 60.9 (10.7)
Diagnosis according to MDQ Positive; N (%) 13 (61.9) 8 (38.1)
Negative; N (%) 63 (95.5) 3 (4.5)
*p < 0.05.
HDRS: Hamilton Depression Rating Score; YMRS: Young Mania Rating Score;
GAF: Global Assessment Functioning; MDQ: Mood Disorder Questionnaire.
ROC curve for MDQ classification respect to SCIDFigure 1
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result is similar to those reported in another study con-
ducted in Spain with patients suffering from major
depression[22].
Nevertheless, SCID may miss some patients who are actu-
ally bipolar. This is mostly related to the inherent limita-
tions of the nosological criteria used that are not
considering many clinical expressions of bipolarity. In
this sense, clinicians will ultimately improve the useful-
ness of screening instruments through their expertise in
recognizing present and past manifestations of bipolar-
ity[23]. In spite of this, the inclusion of an instrument like
MDQ for screening bipolarity in the daily clinical practice
might be very useful in the assessment of patients with a
major depressive episode.
This study has some limitations. The estimate of the sam-
ple size was performed based on the prevalence of bipolar
disorder observed by Hantouche et al. (1998)[1] in a pop-
ulation with major depression. Since the prevalence of
bipolarity in our sample was significantly lower than
expected, the power of the study was reduced to 62%.
Nevertheless, sensitivity and specificity of the MDQ
achieved the level reported in earlier studies.
Further studies are needed to replicate and add new data
about the usefulness of the MDQ as a screening instru-
ment for bipolar disorder in depressive patients.
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